Your browser doesn't support javascript.
Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants.
Guo, Hangtian; Yang, Yixuan; Zhao, Tiantian; Lu, Yuchi; Gao, Yan; Li, Tinghan; Xiao, Hang; Chu, Xiaoyu; Zheng, Le; Li, Wanting; Cheng, Hao; Huang, Haibin; Liu, Yang; Lou, Yang; Nguyen, Henry C; Wu, Chao; Chen, Yuxin; Yang, Haitao; Ji, Xiaoyun.
  • Guo H; The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
  • Yang Y; The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
  • Zhao T; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210008, China.
  • Lu Y; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
  • Gao Y; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
  • Li T; Shanghai Clinical Research and Trial Center, Shanghai, 201210, China.
  • Xiao H; The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
  • Chu X; Yurogen Biosystem LLC, Wuhan, Hubei, 430075, China.
  • Zheng L; The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
  • Li W; The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
  • Cheng H; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University, Nanjing, Jiangsu, 210008, China.
  • Huang H; Yurogen Biosystem LLC, Wuhan, Hubei, 430075, China.
  • Liu Y; Yurogen Biosystem LLC, Wuhan, Hubei, 430075, China.
  • Lou Y; Yurogen Biosystem LLC, Wuhan, Hubei, 430075, China.
  • Nguyen HC; Yurogen Biosystem LLC, Wuhan, Hubei, 430075, China.
  • Wu C; Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
  • Chen Y; Shanghai Clinical Research and Trial Center, Shanghai, 201210, China.
  • Yang H; Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210008, China.
  • Ji X; Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, 210008, China.
Commun Biol ; 6(1): 364, 2023 04 03.
Article in English | MEDLINE | ID: covidwho-2261567
ABSTRACT
Due to the continuous evolution of SARS-CoV-2, the Omicron variant has emerged and exhibits severe immune evasion. The high number of mutations at key antigenic sites on the spike protein has made a large number of existing antibodies and vaccines ineffective against this variant. Therefore, it is urgent to develop efficient broad-spectrum neutralizing therapeutic drugs. Here we characterize a rabbit monoclonal antibody (RmAb) 1H1 with broad-spectrum neutralizing potency against Omicron sublineages including BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, BA.3 and BA.4/5. Cryo-electron microscopy (cryo-EM) structure determination of the BA.1 spike-1H1 Fab complexes shows that 1H1 targets a highly conserved region of RBD and avoids most of the circulating Omicron mutations, explaining its broad-spectrum neutralization potency. Our findings indicate 1H1 as a promising RmAb model for designing broad-spectrum neutralizing antibodies and shed light on the development of therapeutic agents as well as effective vaccines against newly emerging variants in the future.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Commun Biol Year: 2023 Document Type: Article Affiliation country: S42003-023-04759-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Antibodies, Monoclonal Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Language: English Journal: Commun Biol Year: 2023 Document Type: Article Affiliation country: S42003-023-04759-5